Home / Healthcare / Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015

Published: Jul 2015 | No Of Pages: 59 | Published By: Global Markets Direct

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Peripheral Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Peripheral Neuropathy Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11
Diabetic Peripheral Neuropathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Diabetic Peripheral Neuropathy - Products under Development by Companies 15
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 16
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 17
Acorda Therapeutics, Inc. 17
Astellas Pharma Inc. 18
Cebix Incorporated 19
Pfizer Inc. 20
ViroMed Co., Ltd. 21
Diabetic Peripheral Neuropathy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Antimunocel - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ASP-8477 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BNV-222 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
capsaicin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CBX-129801 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug for Pain - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ketoprofen - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NRD-135SE1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PF-05089771 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VM-202 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Diabetic Peripheral Neuropathy - Recent Pipeline Updates 48
Diabetic Peripheral Neuropathy - Dormant Projects 53
Diabetic Peripheral Neuropathy - Discontinued Products 54
Diabetic Peripheral Neuropathy - Product Development Milestones 55
Featured News & Press Releases 55
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 55
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Diabetic Peripheral Neuropathy - Pipeline by Acorda Therapeutics, Inc., H2 2015 17
Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H2 2015 18
Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H2 2015 19
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H2 2015 20
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015 48
Diabetic Peripheral Neuropathy - Dormant Projects, H2 2015 53
Diabetic Peripheral Neuropathy - Discontinued Products, H2 2015 54

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 14
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 23
Number of Products by Stage and Top 10 Targets, H2 2015 23
Number of Products by Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Top 10 Routes of Administration, H2 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 27
Number of Products by Top 10 Molecule Types, H2 2015 29
Number of Products by Stage and Top 10 Molecule Types, H2 2015 29

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +